Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk

Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients

(2014) Raquel Lima de Figueiredo Teixeira et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Human bladder cancer risk calculation based on genome-wide analysis of genetic variants

(2013) H. M. Bolt   ARCHIVES OF TOXICOLOGY

N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients

(2013) N. P. C. Santos et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk

(2012) Silvia Selinski et al.   ARCHIVES OF TOXICOLOGY

NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients

(2012) Hui-Ru An et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples

(2012) Yi Jing He et al.   Pharmacogenetics and Genomics

Impact of population diversity on the prediction of 7-SNP NAT2 phenotypes using the tagSNP rs1495741 or paired SNPs

(2012) Guilherme Suarez-Kurtz et al.   Pharmacogenetics and Genomics

A four-SNP NAT2 genotyping panel recommended to infer human acetylator phenotype

(2012) David W Hein et al.   PHARMACOGENOMICS

Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations

(2012) Guilherme Suarez-Kurtz et al.   PHARMACOGENOMICS

The Differential Effect of NAT2 Variant Alleles Permits Refinement in Phenotype Inference and Identifies a Very Slow Acetylation Genotype

(2012) Jhon D. Ruiz et al.   PLoS One

Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis

(2012) Yu Cai et al.   PLoS One

Distinct SNP Combinations Confer Susceptibility to Urinary Bladder Cancer in Smokers and Non-Smokers

(2012) Holger Schwender et al.   PLoS One

N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians

(2011) V. Leiro-Fernandez et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

(2011) Silvia Selinski et al.   Pharmacogenetics and Genomics

Accuracy of various humanNAT2SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes

(2011) David W Hein et al.   PHARMACOGENOMICS

Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey

(2011) Audrey Sabbagh et al.   PLoS One

Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk

(2010) Marie-Louise Lehmann et al.   ARCHIVES OF TOXICOLOGY

GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis

(2010) L. E. Moore et al.   CARCINOGENESIS

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

(2010) Nathaniel Rothman et al.   NATURE GENETICS

N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine

(2009) David W Hein   Expert Opinion on Drug Metabolism & Toxicology

Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure

(2009) Klaus Golka et al.   Pharmacogenetics and Genomics

Unraveling Ambiguous NAT2 Genotyping Data

(2008) J. A. G. Agundez et al.   CLINICAL CHEMISTRY

Polymorphisms of Human N-Acetyltransferases and Cancer Risk

(2008) Jose Agundez   CURRENT DRUG METABOLISM

Structure/Function Evaluations of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 2

(2008) Jason Walraven et al.   CURRENT DRUG METABOLISM

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

(2008) L. G. Possuelo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Changes in consensus arylamine N-acetyltransferase gene nomenclature

(2008) David W. Hein et al.   Pharmacogenetics and Genomics